An Official ATS/ERSARS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

被引:5681
作者
Raghu, Ganesh
Collard, Harold R.
Egan, Jim J.
Martinez, Fernando J.
Behr, Juergen
Brown, Kevin K.
Colby, Thomas V.
Cordier, Jean-Francois
Flaherty, Kevin R.
Lasky, Joseph A.
Lynch, David A.
Ryu, Jay H.
Swigris, Jeffrey J.
Wells, Athol U.
Ancochea, Julio
Bouros, Demosthenes
Carvalho, Carlos
Costabel, Ulrich
Ebina, Masahito
Hansell, David M.
Johkoh, Takeshi
Kim, Dong Soon
King, Talmadge E., Jr.
Kondoh, Yasuhiro
Myers, Jeffrey
Mueller, Nestor L.
Nicholson, Andrew G.
Richeldi, Luca
Selman, Moises
Dudden, Rosalind F.
Griss, Barbara S.
Protzko, Shandra L.
Schuenemann, Holger J.
机构
关键词
idiopathic pulmonary fibrosis; usual interstitial pneumonia; evidence-based medicine; diagnosis; therapeutics; INTERSTITIAL LUNG-DISEASE; EPSTEIN-BARR-VIRUS; NECROSIS-FACTOR-ALPHA; SURFACTANT PROTEIN-A; PLACEBO-CONTROLLED TRIAL; BRONCHOALVEOLAR LAVAGE FLUID; LOW-DOSE PREDNISOLONE; QUALITY-OF-LIFE; THIN-SECTION CT; RESOLUTION COMPUTED-TOMOGRAPHY;
D O I
10.1164/rccm.2009-040GL
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
This document is an international evidence-based guideline on the diagnosis and management of idiopathic pulmonary fibrosis, and is a collaborative effort of the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Association. It represents the current state of knowledge regarding idiopathic pulmonary fibrosis (IPF), and contains sections on definition and epidemiology, risk factors, diagnosis, natural history, staging and prognosis, treatment, and monitoring disease course. For the diagnosis and treatment sections, pragmatic GRADE evidence-based methodology was applied in a question-based format. For each diagnosis and treatment question, the committee graded the quality of the evidence available (high, moderate, low, or very low), and made a recommendation (yes or no, strong or weak). Recommendations were based on majority vote. It is emphasized that clinicians must spend adequate time with patients to discuss patients' values and preferences and decide on the appropriate course of action.
引用
收藏
页码:788 / 824
页数:37
相关论文
共 322 条
[1]   Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis [J].
Akagi, Takanori ;
Matsumoto, Takemasa ;
Harada, Taishi ;
Tanaka, Makoto ;
Kuraki, Takashige ;
Fujita, Masaki ;
Watanabe, Kentaro .
RESPIRATORY MEDICINE, 2009, 103 (08) :1209-1215
[2]   CT findings during phase of accelerated deterioration in patients with idiopathic pulmonary fibrosis [J].
Akira, M ;
Hamada, H ;
Sakatani, M ;
Kobayashi, C ;
Nishioka, M ;
Yamamoto, S .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1997, 168 (01) :79-83
[3]  
Al-Hameed Fahad M, 2004, Can Respir J, V11, P117
[4]   Short telomeres are a risk factor for idiopathic pulmonary fibrosis [J].
Alder, Jonathan K. ;
Chen, Julian J. -L. ;
Lancaster, Lisa ;
Danoff, Sonye ;
Su, Shu-Chih ;
Cogan, Joy D. ;
Vulto, Irma ;
Xie, Mingyi ;
Qi, Xiaodong ;
Tuder, Rubin M. ;
Phillips, John A., III ;
Lansdorp, Peter M. ;
Loyd, James E. ;
Armanios, Mary Y. .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (35) :13051-13056
[5]   Idiopathic pulmonary fibrosis: is it a familial disease? [J].
Allam, J. Shirine ;
Limper, Andrew H. .
CURRENT OPINION IN PULMONARY MEDICINE, 2006, 12 (05) :312-317
[6]   Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis [J].
Allen, S ;
Raut, S ;
Woollard, J ;
Vassallo, M .
PALLIATIVE MEDICINE, 2005, 19 (02) :128-130
[7]   ADVANCED CRYPTOGENIC FIBROSING ALVEOLITIS - PRELIMINARY-REPORT ON TREATMENT WITH CYCLOSPORINE-A [J].
ALTON, EWFW ;
JOHNSON, M ;
TURNERWARWICK, M .
RESPIRATORY MEDICINE, 1989, 83 (04) :277-279
[8]  
Ambrosini V, 2003, EUR RESPIR J, V22, P821, DOI 10.1183/09031936.03.00022703
[9]  
[Anonymous], 1980, Ann Intern Med, V93, P391
[10]  
[Anonymous], 2000, AM J RESP CRIT CARE, V161, P646, DOI DOI 10.1164/AJRCCM.161.2.ATS3-00